Device Registration China

Medical device registration in China begins with determining the device classification and applicable NMPA pathway. Foreign manufacturers must appoint an NMPA Legal Agent, complete required testing and technical documentation, prepare the registration dossier, submit it through the eRPS system, and undergo the applicable technical and administrative review before receiving the required certificate or filing confirmation.

Foreign medical device manufacturers entering China must comply with NMPA requirements and appoint a local NMPA Legal Agent. Depending on the device class, requirements may include product testing, technical documentation, safety and performance evidence, clinical evaluation, Chinese-language materials, labeling, and electronic submission through the applicable NMPA registration process.

An NMPA Legal Agent is the in-country representative appointed by a foreign medical device manufacturer for regulatory activities in China. The Legal Agent communicates with NMPA, manages registration submissions and updates, and helps maintain regulatory documentation. According to the provided page, appointing an NMPA Legal Agent is mandatory for foreign applicants.

China classifies medical devices into Class I, Class II, and Class III according to the applicable NMPA classification rules and Medical Device Classification Catalogue. Class I devices are considered lower risk, Class II devices medium risk, and Class III devices higher risk. Classification determines the applicable registration or filing pathway and review requirements.

Class I medical devices generally follow an administrative record-filing pathway with relatively limited technical review. Class II and Class III devices require formal registration and more detailed technical evaluation. Their submissions may include product testing, safety and performance information, and clinical evaluation-related evidence depending on the device and applicable NMPA requirements.

NMPA registration documentation depends on the device classification and regulatory pathway. The submission may include technical documentation, product testing information, safety and performance data, clinical evaluation materials, labeling, quality-system information, and other required registration documents. Foreign manufacturers must also address Chinese-language submission and localization requirements where applicable.

Product testing can be an important part of China NMPA registration, particularly for Class II and Class III devices. The provided pathway includes testing through NMPA-designated laboratories before submission. Testing requirements depend on the device, applicable standards, classification, and regulatory pathway, so manufacturers should establish the testing strategy early in the registration process.

Clinical evaluation requirements depend on the device, its classification, applicable NMPA requirements, and available supporting evidence. For Class II and Class III devices, the registration process may require clinical evaluation-related documentation, while predicate device identification can help determine the appropriate evidence pathway. The specific clinical requirements should be assessed for each product.

Registration timelines vary according to device classification, technical complexity, testing requirements, clinical evidence, and review activities. The provided page indicates an approximate timeline of about one day for Class I filing, one to two years for Class II registration, and two or more years for Class III registration. Actual timelines can vary by product and submission.

According to the provided page, Class II and Class III medical device registration certificates have a five-year validity period and require renewal. Class I devices follow a filing pathway and are listed with unlimited validity. Manufacturers must also manage applicable changes, renewals, fees, regulatory communications, and other lifecycle obligations after registration.